Chronic hepatitis C virus hepatitis and psoriasis: No longer a contraindication to interferon use in the era of biological agents?

Abstract

We describe a patient with severe psoriasis and hepatitis C simultaneously treated with pegylated interferon alpha (peg-IFNα) plus ribavirin and etanercept, whose skin lesions improved and who reached a sustained virological response. This case suggests that refractory psoriasis can today no longer be considered as a contraindication for combined hepatitis C virus treatment.

Keywords::

• HCV hepatitis
• psoriasis
• peg-IFNα
• ribavirin
• etanercept

Acknowledgements

We would like to thank Scarlett Laroma, English mother tongue speaker, whose work has been very helpful in editing this paper.

Declaration of interest: There is no financial support and conflict of interest in this work.